ResMed Inc. (RMD), a leader in sleep and respiratory care devices including CPAP machines and digital health solutions, continues to demonstrate resilient growth amid a macroeconomic environment favoring healthcare innovation. With an aging global population and rising prevalence of obstructive sleep apnea (OSA) driven by obesity trends, the company has capitalized on secular tailwinds. Over the past decade, ResMed’s revenue has more than doubled from $1.84 billion in 2016 to $4.69 billion in 2024—a compound annual growth rate (CAGR) of approximately 12%—outpacing broader medtech peers. This trajectory reflects not just organic expansion but strategic pivots, such as the 2021 acquisition of Brightree for $800 million, which bolstered its SaaS offerings in out-of-hospital care, and navigation through COVID-19 disruptions where ventilator demand surged in 2020 before normalizing. Recent analyst forecasts project revenue climbing to $5.15 billion in 2025 (10% YoY growth), $5.65 billion in 2026 (10% YoY), and $6.06 billion in 2027 (7% YoY), signaling sustained momentum despite potential headwinds from weight-loss drugs like GLP-1 agonists, which could mildly suppress OSA incidence but are offset by ResMed’s software margins.
Revenue Expansion and Operational Efficiency
A standout metric is revenue per employee, which has risen from $350,000 in 2016 to $469,000 in 2024, underscoring productivity gains even as headcount grew 90% to nearly 10,000. This efficiency—important for scalability in a labor-intensive medtech sector—correlates tightly with gross margins stabilizing around 56-59%, dipping slightly in 2023 due to supply chain pressures from geopolitical tensions (e.g., U.S.-China trade frictions impacting Asian manufacturing) before rebounding to an estimated 59% in 2025. Revenue per share has similarly advanced from $13.11 to $31.87 (143% increase), aligning with modest share count stability at ~147 million, reflecting disciplined capital allocation over aggressive buybacks.
Stock price performance mirrors this growth but with volatility tied to macro cycles. Annual highs climbed from $71 in 2016 to $260 in 2024 (266% gain), while lows expanded from $51 to $164 (223% gain), indicating reduced downside risk over time. Notably, the 2022 dip (high $262, low $189) coincided with post-COVID normalization and inflation spikes eroding consumer spending on elective devices, yet fundamentals held firm with revenue up 15% YoY to $3.58 billion. By 2024, prices recovered to highs near $293 estimated, tracking EPS growth from $2.51 to a projected $9.55 in 2025 (281% cumulative rise).
Profitability Surge and Margin Expansion
Earnings before tax (EBT) have accelerated, reaching $1.26 billion in 2024 (15% YoY growth from $1.10 billion in 2023) with margins expanding to 27% and forecasted at a robust 33% in 2025—key for investor confidence as it signals pricing power and cost controls amid rising input costs from global energy volatility. Net income followed suit, hitting $1.02 billion in 2024 (14% YoY increase) and projected at $1.41 billion in 2025 (37% YoY jump), driven partly by lower effective taxes and SaaS scaling. Return on equity (ROE) remains elite at 20-27%, averaging 22% over the decade, far above the S&P 500 healthcare average of ~15%, highlighting efficient reinvestment in R&D (implicit via depreciation up 149% to $216 million).
This profitability uptick inversely correlates with valuation compression: trailing P/E fell from a peak 75x in 2021 (COVID euphoria) to 27x in 2024, now forward-looking at ~24x for 2025 based on EPS estimates. PS ratios similarly moderated from 11x to 5.9x, suggesting the stock trades at a discount to historical norms relative to sales growth, especially as EV/Sales dips to ~6x forward.
Cash Flow Strength and Balance Sheet Resilience
Free cash flow per share tells a compelling story of maturity, surging from $3.42 in 2016 to $8.75 in 2024 (156% increase), with 2024’s $1.29 billion absolute FCF (130% YoY from $559 million) fueled by operating cash flow doubling to $1.40 billion. This metric is crucial for funding capex (stable at ~$115 million) and dividends, while net debt flipped to a cash position of -$551 million in 2024 from $1.17 billion gross debt in 2016—a deleveraging trend (debt down 44% in recent years) that fortifies against rate hikes seen in 2022-2023. Shareholder equity ballooned 187% to $4.86 billion, supporting book value per share up 174% to $33, with PB ratio normalizing to 5.7x.
Correlations here are stark: FCF growth tracks revenue but amplifies via margin leverage, enabling ROIC peaks near 19% estimated for 2025. Post-2020, when capex/share bottomed amid pandemic uncertainty, cash generation rebounded, cushioning 2022’s FCF dip to $1.34/share (75% below prior year) tied to working capital swings.
Insider Activity and Signaling
Insider transactions reveal zero buys but consistent sells totaling ~$39 million from March 2025 to February 2026, often monthly patterns suggestive of pre-scheduled 10b5-1 plans rather than bearish signals. CEO and CFO led with recurring blocks (e.g., CEO ~8,000 shares monthly at escalating prices from ~$210 to ~$275 equivalents), alongside directors unloading 2,000-share lots. While volume is modest relative to market cap, the absence of buys amid strong fundamentals might temper enthusiasm, though transaction prices align with recent trading levels, implying confidence in stability rather than distress selling.
Analyst Forecasts and Future Trajectory
Looking ahead, analysts envision EPS reaching $10.59 in 2026 (11% YoY from 2025) and $11.81 in 2027, with revenue per share hitting $38.75 and $41.66 respectively. EBT projections top $1.77 billion in 2026, implying sustained 30%+ margins if SaaS adoption accelerates—critical as digital health now contributes ~20% of revenue, less cyclical than hardware. Challenges include reimbursement pressures in Medicare (U.S. ~50% of sales) and competition from Philips (post-recall recovery), but ResMed’s 70%+ U.S. OSA market share and international expansion (e.g., Europe/Asia growth) position it well. Macro tailwinds like U.S. healthcare spending at 18% of GDP and global OSA prevalence (1 billion undiagnosed cases per WHO) support 8-10% CAGR through 2028.
Valuation Relative to Current Levels
At recent close, the stock embeds reasonable upside. Analyst means suggest ~24% potential appreciation, with highs implying ~47% and lows -9%—a spread reflecting debate on GLP-1 impacts versus innovation pipeline (e.g., AirSense 11 device launches). Compared to 2024’s 27x forward P/E, implied multiples contract to 24x and 21x by 2026-2027, attractive versus medtech peers at 30x+. EV/FCF at ~23x forward remains compelling given $1.65 billion 2025 FCF estimate (28% YoY growth).
In sum, ResMed’s fundamentals—revenue compounding, margin expansion, cash fortification—have propelled stock gains that, while volatile, increasingly hug intrinsic value. Geopolitical stability in supply chains and demographic-driven demand could unlock further re-rating, making it a defensive growth play in uncertain times. Investors should monitor Q1 2026 earnings for SaaS traction amid insider sales rhythm.
(Word count: 1,128)